D. Western Therapeutics Institute, Inc. (TYO:4576)

Market Cap	5.30B
Revenue (ttm)	471.00M
Net Income (ttm)	-1.29B
Shares Out	45.28M
EPS (ttm)	-36.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	407,100
Average Volume	909,255
Open	118.00
Previous Close	117.00
Day's Range	117.00 - 121.00
52-Week Range	60.00 - 254.00
Beta	-0.08
RSI	64.17
Earnings Date	May 15, 2025

About TYO:4576

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4576

Financial Performance

In 2024, TYO:4576's revenue was 471.00 million, an increase of 10.05% compared to the previous year's 428.00 million. Losses were -1.29 billion, 58.9% more than in 2023.